Clinical trial of rosuvastatin in lipid regulation guided by ApoE and SLCO1B1 genes
Objective To study the efficacy and safety of apolipoprotein E(ApoE)gene and solute carrier organic anion transporter family 1B1(SLCO1B1)gene guided rosuvastatin in regulating lipid.Methods According to ApoE genotype,patients with dyslipidemia were divided into E2 group(ε2/ε2,ε2/ε3),E3 group(ε3/ε3,ε2/ε4)and E4 group(ε3/s4,ε4/ε4).According to SLCO1B1 genotype,they were divided into TT group(*1a/*1a,*la/*1b,*lb/*lb),TC group(*la/*5,*1a/*15,*lb/*15)and CC group(*15/*15).All patients were given rosuvastatin calcium tablets 10 mg each time,once a night,orally for 6 months.The levels of triglyceride(TG),total cholesterol(TC),low density lipoprotein cholesterol(LDL-C)and high-density lipoprotein cholesterol(HDL-C)in three groups of ApoE genotype patients were compared.The levels of alanine aminotransferase(GPT),glutamic-oxalacetic aminotransferase(GOT),creatine kinase(CK),creatinine(Cr),fasting blood glucose(FBG)and glycated hemoglobin(HbA1C)in SLCO1B1 genotype patients in 3 groups;the occurrence of myalgia during the study period was observed.Results A total of 1 693 patients were included,including 204 patients in E2 group,1 226 patients in E3 group and 263 patients in E4 group.Among them,there were 1 340 cases in TT group,334 cases in TC group and 19 cases in CC group.After rosuvastatin treatment,the TG levels of E2,E3 and E4 groups were(1.34±1.17),(1.20±0.43)and(1.34±0.55)mmol·L-1;the LDL-C levels were(1.84±0.52),(2.09±0.66)and(2.25±0.51)mmol·L-1;the HDL-C levels were(1.20±0.26),(1.13±0.27)and(1.01±0.21)mmol·L-1.Compared with the E3 and E4 groups,the levels of TG and LDL-C in E2 group were significantly decreased;the HDL-C levels in E2 and E3 groups were significantly higher than that in E4 group(all P＜0.05).After rosuvastatin treatment,the CK levels in CC group were significantly higher than that in TT and TC groups(113 vs 96,94 U·L-1,all P＜0.05).The incidences of myalgia in TT,TC and CC groups were 3.13％,5.99％and 10.53％(P＜0.05).Conclusion After rosuvastatin treatment,ε2 allele and E2/E3 genotype were more effective in reducing TG and LDL-C levels in patients with dyslipidemia.SLCO1B1 521T＞C:CC genotype is more prone to myalgia,521T＞C genotypes did not lead to diabetes.
rosuvastatin calcium tabletapolipoprotein E genesolute carrier organic anion transporter family 1B1gene polymorphismabnormal lipid profile
万方数据
维普
